Concert Pharma mit Alzheimer Agi. in Phase III

http://www.concertpharma.com/product-pipeline/

Kurs aktuell: 16,28USD +2,25USD + 16,04%
Kursziel aktuell (20 USD):

http://www.finanzen.net/analyse/...als_Buy-H_C_Wainwright__Co__617011

RT http://www.nasdaq.com/de/symbol/cnce/real-time

About: http://www.concertpharma.com/  

kann ich nicht überall an Board sein :)  

http://www.nasdaq.com/de/symbol/cnce/real-time

...jetzt könnte man mal über einen Einstieg nachdenken :)  

https://www.fiercebiotech.com/biotech/...fter-loss-incyte-patent-case  

https://www.finanzen.net/analyse/...Pharmaceuticals_Buy-Mizuho_638515  

https://www.reuters.com/article/...%28News+%2F+US+%2F+Company+News%29  

http://www.analystratings.com/articles/...buy-from-mizuho-securities/  

https://seekingalpha.com/news/...us-543-data-stoked-selloff-5-percent  

https://www.zacks.com/stock/news/378611/...ystage-schizophrenia-study  

Concert Pharmaceuticals meldet Zahlen für Q2/19

• keine Umsätze
  
• Verlust 19 Mio. $
  
• Cash 136 Mio. $
  
• MK 250 Mio. $
  

https://ir.concertpharma.com/news-releases/...-quarter-2019-financial

 

AVP-786 Phase 3 Studie floppt und verfehlt sowohl primäre als auch sekundäre Endpunkte

https://seekingalpha.com/news/...failed-late-stage-avpminus-786-study

 

Zahlen für Q3/19

• keine signifikanten Umsätze
  
• Verlust 17 Mio. $
  
• Cash 122 Mio. $
  
• MK 153 Mio. $
  

https://ir.concertpharma.com/news-releases/...-quarter-2019-financial

 

https://www.rttnews.com/3061951/...s-fda-in-feb-all-eyes-on-agtc.aspx  

https://ir.concertpharma.com/news-releases/...ice-allowance-us-patent  

65 Mio. $ Offering

https://ir.concertpharma.com/news-releases/...icing-public-offering-0

 

Cash bis zweite Hälfte 2021

Cash and Investment Position. Cash, cash equivalents and investments as of March 31, 2020, totaled $159.6 million as compared to $106.4 million as of December 31, 2019. In the first quarter of 2020, Concert closed a public offering of common stock and pre-funded warrants, raising net proceeds of approximately $70 million. Under its current operating plan, the Company expects its cash, cash equivalents and investments to fund the Company into the second half of 2021.

https://ir.concertpharma.com/news-releases/...-quarter-2020-financial  

https://old.nasdaq.com/de/symbol/cnce/real-time  

CTP-692 Phase 2 Studie (Schizophrenie) verfehlt den primären Endpunkt

https://ir.concertpharma.com/news-releases/...s-ctp-692-phase-2-trial

 

Kleiner Alert von meiner Watchlist. Bei CNCE gab es heute ein neues 52 WT.

Zahlen für Q4/20

• keine signifikanten Umsätze
  
• Verlust 22 Mio. $
  
• Cash 130 Mio. $
  
• MK 151 Mio. $
  

"Under its current operating plan, the Company expects its cash, cash equivalents and investments to fund the Company through 2021"

https://ir.concertpharma.com/news-releases/...0-financial-results-and

 

 

Wieder ein Alert auf meiner WL

Zahlen für Q1/21

• keine Umsätze
  
• Verlust 23 Mio. $
  
• Cash 112 Mio. $
  
• MK 128 Mio. $
  

expects its cash, cash equivalents and investments to fund the Company through 2021

CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023

https://ir.concertpharma.com/news-releases/...-quarter-2021-financial

 

Verkauf von Meilensteinansprüchen an Vertex

• Mitte Mai 2021 hat CNCE für 32 Mio. $ alle zukünftigen Meilensteilenzahlungen für VX-561 an VRTX verkauft
  
• 2017 hatte CNCE  VX-561 (deutivacaftor) für 160 Mio. $ Cash + bis zu 90 Mio. $ an Meilensteinzahlungen verkauft
  

“By receiving these proceeds, we now expect our cash, cash equivalents and investments to fund the Company into the second quarter of 2022.”

https://ir.concertpharma.com/news-releases/...x-561-milestones-vertex

 

THRIVE-AA1 Phase 3  Topline Daten (von  CTP-543 in Alopecia Areata) in Q2/22

https://ir.concertpharma.com/news-releases/...ment-thrive-aa1-phase-3

 

 

Sun Pharma bietet für Concert Pharmaceuticals

• 8,00$ Cash je Aktie
  
• und CVR´s von bis zu 3,50$ (Meilensteinabhängig)
  

https://ir.concertpharma.com/news-releases/...als-advancing-potential